These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33480649)

  • 1. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
    Baig MU; Rytting M; Roth M; Morani AC; Nunez C; Lin P; Cuglievan B
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e991-e996. PubMed ID: 33480649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.
    Farhadfar N; Li Y; May WS; Adams CB
    Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):246-251. PubMed ID: 32199933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.
    Zhu Y; Dai Y; Tang X
    Ann Hematol; 2022 Nov; 101(11):2525-2528. PubMed ID: 36063200
    [No Abstract]   [Full Text] [Related]  

  • 4. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
    Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
    Kong J; Chen N; Li M; Zhang J; Wu X; Zong L; Wu D; Song B; Qiu H
    Ann Hematol; 2022 Mar; 101(3):697-699. PubMed ID: 33954816
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
    [No Abstract]   [Full Text] [Related]  

  • 8. Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    El-Cheikh J; Moukalled NM; El Darsa H; Massoud R; Kanj SS; Mahfouz R; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e441-e444. PubMed ID: 30166258
    [No Abstract]   [Full Text] [Related]  

  • 9. Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
    Wang H; Bai J; Pei Z; Zhang B; Wang J; Lian X; Song Q
    Medicine (Baltimore); 2020 Nov; 99(47):e23265. PubMed ID: 33217852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
    Zhang X; Li J; Jin J; Yu W
    Ann Hematol; 2020 Feb; 99(2):395-397. PubMed ID: 31879788
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
    DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
    Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
    Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
    Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
    Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
    Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Pillai R; Sanchez JF; Mei M; Aribi A; Ali H; Sandhu K; Al Malki MM; Salhotra A; Khaled S; Sun W; O'Donnell M; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Am J Hematol; 2019 Oct; 94(10):E253-E255. PubMed ID: 31259427
    [No Abstract]   [Full Text] [Related]  

  • 17. Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.
    Molina JC; Asare JM; Tuschong L; West RR; Calvo KR; Persky R; Boyce AM; Hammoud DA; Holland SM; Hickstein D; Shah NN
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28865. PubMed ID: 33369023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
    Wan CL; Zou JY; Qiao M; Yin J; Shen XD; Qiu QC; Liu SB; Xue SL
    Leuk Lymphoma; 2021 Dec; 62(13):3300-3303. PubMed ID: 34323656
    [No Abstract]   [Full Text] [Related]  

  • 19. RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
    Chow S; Tang K; Al-Abri M; Hall V; Tremblay-Lemay R; Rashedi I; Tsui H; Chan SM
    Leuk Res; 2021 Dec; 111():106735. PubMed ID: 34735933
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypomethylating agents and venetoclax in acute myeloid leukemia.
    DiNardo CD
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.